The study compared CARVYKTI's efficacy and safety against standard-of-care regimens in patients with multiple myeloma.

Johnson & Johnson (JNJ) said that Health Canada has issued a Notice of Compliance for CARVYKTI (ciltacabtagene autoleucel) for the ...

Authorization is based on results from the Phase 3 CARTITUDE-4 (MMY3002) study, which showed treatment with CARVYKTI® reduced the risk of disease progression or death by 74 per cent compared to ...

We recently compiled a list of the 12 NASDAQ Stocks with Biggest Upside Potential According to Analysts. In this article, we ...

The study – which tested Carvykti in patients with one to three lines of prior therapy – gives J&J an opportunity to leapfrog Bristol-Myers Squibb and 2Seventy bio's rival BCMA CAR-T therapy ...

Johnson & Johnson and Legend Biotech’s BCMA-targeted CAR-T therapy Carvykti has been approved by the FDA to treat patients with multiple myeloma after at least one prior therapy. The decision ...

We recently compiled a list of the 10 Worst Performing Biotech Stocks in 2024. In this article, we are going to take a look ...

ABBV stock has seen strong gains of 85% from levels of $90 in early January 2021 to around $165 now, vs. an increase of about ...

Santhosh K. Sadashiv, MD, discusses the role of chimeric antigen receptor T-cell therapy in patients with multiple myeloma.

With their push to end smoking in Atlantic City's casinos going nowhere fast in either the courts or the state Legislature, casino workers and supporters of smoke-free gambling halls demonstrated ...

Legend Biotech Corp (LEGN) reports significant sales growth for CARVYKTI, despite facing increased expenses and a net loss in Q3 2024. Although the revenue and EPS for Legend Biotech (LEGN ...

已经撤市的Blenrep，曾被视为GSK重回肿瘤战场的一把利器。无论是BCMA这个靶点，还是ADC这一分子类型，这款产品过去都因为抗肿瘤方面的潜力而名声在外。GSK不愿放弃这个“失败”的产品。去年，它重提对Blenrep高达30亿英镑的野望。眼下，这 ...